FabI (enoyl-acyl carrier protein reductase): a key target for the development of antibacterial agents
Antimicrobial resistance (AMR) is currently a serious threat to human health. Consequently, the development of new antibacterial agents targeting underexplored bacterial pathways and thereby circumventing existing resistance mechanisms is urgent. The widely conserved bacterial type II fatty acid synthesis (FAS-II) pathway represents an attractive target to tackle antimicrobial resistance. FAS-II is mediated by a series of Fab enzymes. Among these, enoyl-acyl carrier protein reductase (ENR) catalyzes the reduction of a double bond in enoyl-ACP to acyl-ACP, a crucial step in bacterial fatty acid biosynthesis. In humans, fatty acid biosynthesis occurs via a distinct multi-enzyme FAS-I complex, making FAS-II enzymes promising targets for the development of new antibacterial agents. FabI is the most extensively characterized ENR and is widely distributed among clinically relevant bacterial pathogens. Besides FabI, alternative ENRs, including FabK, FabL, FabV, and the mycobacterial homolog InhA, have been identified in different microorganisms. FabI represents a validated antibacterial target, with several covalent and non-covalent FabI inhibitors having emerged as potential antibiotics. Among these, advanced clinical candidates such as afabicin and nilofabicin have demonstrated the therapeutic potential of ENR inhibition. This review summarizes the FabI structure, the catalytic mechanism, the ENR diversity, and the major classes of reported FabI inhibitors. Taken together, these insights provide a foundation for the rational development of next-generation antibacterial agentes. This review summarizes the FabI structure, the catalytic mechanism, the ENR diversity, and the major classes of reported FabI inhibitors. Taken together, these insights provide a foundation for the rational development of next-generation antibacterial agentes.
Authors
- Gabriel Corrêa Veríssimo (ORCID: https://orcid.org/0000-0001-7480-7198)
- Raquel Goes de Castro (ORCID: https://orcid.org/0000-0002-0334-7136)
- Débora Maria Abrantes Costa (ORCID: https://orcid.org/0000-0001-7628-1871)
- Mateus Sá Magalhães Serafim
- Fernanda Kelly Marcelino e Oliveira
Institutions
- Universidade Federal de Minas Gerais (BR)
Publication Details
- Journal
- Frontiers in Drug Discovery
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3389/fddsv.2026.1947040
- Primary Topic
- Microbial Natural Products and Biosynthesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais
- Universidade Federal de Minas Gerais